LSD for Health & Longevity

Evidence Review created on 08/06/2026 using AI4L / Opus 5

Also known as: Lysergic Acid Diethylamide, Lysergide, LSD-25, Lysergide D-Tartrate, MM120, DT120, Delysid, Acid

Motivation

LSD (lysergic acid diethylamide) is a laboratory-made compound derived from a fungus that grows on rye. Taken by mouth in amounts measured in millionths of a gram, it alters perception, mood, and sense of self for most of a day, acting mainly on one family of serotonin receptors in the brain. Interest has returned because supervised single sessions are again being tested for lasting effects on anxiety and drinking.

Discovered in 1938 and studied intensively through the 1950s and 1960s, it was withdrawn and outlawed in most countries by 1970, and formal research stopped for roughly three decades. Controlled trials resumed in the 2010s, a standardized form is now in late-stage testing for long-standing anxiety, and an informal culture of very small, non-intoxicating doses has grown alongside it.

This review examines what the evidence shows about LSD in the context of health and long-term well-being: how it acts in the body, which benefits and harms controlled research supports and how strongly, how sessions and low-dose schedules are structured, and where the evidence remains thin or disputed.

Benefits - Risks - Protocol - Conclusion

Recommended Reading

A short list of high-level overviews of LSD and psychedelic-assisted therapy from independent experts and health-research publications.

• Dr. Matthew Johnson: Psychedelic Medicine - Andrew Huberman

  A long-form conversation with a Johns Hopkins researcher covering how classic psychedelics including LSD are dosed, screened for, and supervised in clinical trials, and what the trial data do and do not show for depression, addiction, and trauma. It is the most practically detailed overview of trial methodology among the five items.

• #182 – David Nutt: Psychedelics & Recreational Drugs - Peter Attia

  A framework-driven discussion of how the measured harm of LSD compares with alcohol, opioids, and stimulants, and how its regulatory classification diverged from that measurement. David Nutt chairs Drug Science, an advocacy organization whose funding and public standing depend on psychedelics being reclassified, so his harm rankings are presented here as an argued position rather than a neutral audit.

• RHR: The Emerging Field of Psychedelic-Assisted Psychotherapy, with Dr. Ingmar Gorman - Chris Kresser

  A clinician-facing episode on how psychedelic-assisted psychotherapy is actually delivered — screening, preparation, the supervised session, and integration afterwards — and on the drawbacks of the field’s rapid popularization. Useful for understanding why the therapy container, not the molecule alone, is treated as part of the intervention.

• Roland Griffiths, Ph.D. on Psilocybin, Psychedelic Therapies & Mystical Experiences - Rhonda Patrick

  A detailed interview with the researcher who restarted rigorous psychedelic trials in the United States, covering dose-dependent subjective effects, the mystical-experience construct that also predicts LSD outcomes, and the safeguards that keep serious adverse events rare. It explains the mechanism-of-experience thinking that underlies modern LSD protocols.

• Anxiety and Anxiety Disorders: Overview - Life Extension

  A referenced treatment protocol whose dedicated “Psychedelic Therapy” section traces LSD from its 1940s discovery through the two treatment traditions of the classical era to the modern controlled trials, and summarizes the LSD-assisted psychotherapy result in life-threatening illness alongside the psilocybin work. It is the one source here that situates LSD inside a conventional supplement-and-pharmacology framing of anxiety management rather than inside psychedelic research itself.

Grokipedia

• LSD

  A dense, heavily referenced overview covering the 1938 synthesis, receptor pharmacology, dose-response, the 1950s and 1960s clinical record, prohibition, and the modern trial revival. It is notable for explicitly contrasting empirical harm rankings against the compound’s legal scheduling.

Examine

• LSD

  Examine’s dedicated intervention page for the compound, last updated in August 2025, which frames LSD as a psychedelic with preliminary evidence for psychiatric use and links its curated feed of individual study summaries. Its value is as an independent, non-commercial index of which specific LSD studies have been appraised.

ConsumerLab

No ConsumerLab article on LSD exists. ConsumerLab tests dietary supplements and over-the-counter products; LSD is a controlled substance and an investigational medicine that is not sold as a supplement, and the organization does not typically cover prescription or scheduled medications.

Systematic Reviews

Systematic reviews and meta-analyses that pool controlled LSD data on efficacy, tolerability, and long-term safety.

• Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis - Hsu et al., 2024

  The most methodologically careful comparison of psychedelics against a standard antidepressant, and the one that most constrains enthusiasm: once placebo response was calibrated to antidepressant-trial norms rather than psychedelic-trial norms, only high-dose psilocybin beat placebo, and LSD did not separate. It is the key counterweight to single-trial effect sizes.

• Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials - Krebs & Johansen, 2012

  Pools six randomized controlled trials from the 1960s and early 1970s covering 536 participants and finds a consistent benefit of a single dose on alcohol misuse with essentially no between-trial heterogeneity (heterogeneity — how much the individual studies disagree with one another). It is the quantitative basis for the claim that the historical alcoholism work was real rather than anecdotal.

• The potential role of lysergic acid diethylamide for psychological assisted therapy: A meta-analysis of randomised controlled trials in healthy volunteers - Li et al., 2022

  Pools five modern randomized controlled trials in 132 healthy volunteers to map the dose-response for subjective mood effects, blood pressure, heart rate, body temperature, and adverse effects. It is the cleanest source for what a given microgram amount actually does in a person without a psychiatric diagnosis.

• Side effects of microdosing lysergic acid diethylamide and psilocybin: A systematic review of potential physiological and psychiatric outcomes - Modzelewski et al., 2025

  The only systematic synthesis focused specifically on the harms of repeated low-dose use, drawing on 31 studies and separating higher-quality laboratory work from self-report surveys. It identifies raised blood pressure, anxiety, and cognitive impairment as the recurring dose-dependent signals.

• Cardiac Consequences Associated with Psychedelic Use: A Systematic Review of Lysergic Acid Diethylamide, 3,4-Methylenedioxymethamphetamine, and 5-Hydroxytryptamine 2B-Mediated Valvular Heart Disease - Xu et al., 2026

  Reviews seventeen studies on whether repeated psychedelic exposure could scar heart valves through the same receptor pathway implicated in fenfluramine and ergot-derived medications. It is the most directly relevant safety analysis for anyone contemplating years of scheduled low-dose use rather than one or two supervised sessions.

Mechanism of Action

LSD’s primary action is agonism (activation) at the serotonin 2A receptor, written 5-HT2A (a receptor concentrated on the large pyramidal neurons of the cortex, the outer layer of the brain that handles perception and abstract thought). Blocking this receptor with ketanserin abolishes essentially all of LSD’s subjective effects, which is the strongest available evidence that 5-HT2A activation is the necessary gateway.

Three features distinguish LSD from other 5-HT2A agonists.

• Unusually slow receptor dissociation: crystallography shows LSD binds under a flexible “lid” formed by an extracellular loop of the receptor, so it detaches very slowly. This is the leading structural explanation for why effects last eight to twelve hours from a single oral dose, far longer than the compound’s presence in blood would predict.

• Biased signalling: LSD preferentially recruits β-arrestin2 (an intracellular signalling adaptor that shuts down and internalizes receptors) in addition to the classical G-protein pathway. Biased recruitment is thought to drive both the prolonged effect and, separately, the fibrotic signalling concern at the 5-HT2B receptor.

• Broad receptor promiscuity: beyond 5-HT2A, LSD has meaningful affinity for 5-HT1A, 5-HT2B, 5-HT2C, 5-HT6, and 5-HT7 serotonin receptors, for dopamine D1 and D2 receptors, and for α-adrenergic receptors. The dopamine D2 component is thought to shape the later half of the experience; the 5-HT2B component carries the heart-valve concern discussed under risks.

Downstream of the receptor, two partly competing accounts exist for the lasting effects.

• The network-disruption account: functional brain imaging consistently shows that LSD desegregates the default mode network — a set of midline regions most active during self-referential thought and rumination — and increases communication between networks that are normally separate. Global brain entropy rises acutely, and the size of that rise has been correlated with greater trait openness two weeks later. On this account, the lasting benefit is a consequence of the subjective experience.

• The psychoplastogen account: on this view LSD is a psychoplastogen (a compound that rapidly promotes structural remodelling of brain circuits). LSD acutely increases signalling through BDNF (brain-derived neurotrophic factor, a protein that promotes the growth and survival of neurons) and its receptor TrkB, and through mTOR (mechanistic target of rapamycin, a master regulator of cell growth and protein synthesis), producing measurable growth of dendritic spines in preclinical models. On this account, structural plasticity is the active ingredient and the subjective experience is a side effect. The dispute matters practically, because non-hallucinogenic 5-HT2A agonists are being developed on the assumption that the second account is correct, and the failure of low, non-perceptual doses to produce durable clinical benefit in controlled trials is the strongest evidence against it.

Key pharmacological properties, from controlled pharmacokinetic studies in healthy volunteers:

• Half-life: approximately 3 to 5 hours for the parent compound, with nonlinear kinetics — the half-life lengthens at higher doses. Subjective effects outlast measurable plasma levels because of the slow receptor dissociation described above.

• Onset and peak: effects begin at 20 to 60 minutes after an oral dose; peak plasma concentration occurs at roughly 1.5 hours; total duration is 8 to 11 hours at 100 to 200 micrograms and 6 to 8 hours at 50 micrograms.

• Selectivity: high affinity at 5-HT2A, with the receptor-occupancy studies in humans indicating that most of the perceptual effect is captured well below full receptor saturation. It is not a selective compound.

• Tissue distribution: highly lipophilic (fat-soluble), crosses the blood-brain barrier rapidly, with an oral bioavailability of roughly 70 percent. Plasma protein binding is high, and the volume of distribution is moderate.

• Metabolism: hepatic, with CYP2D6 (a liver enzyme that also processes many antidepressants, opioids, and beta-blockers, and whose activity varies widely by genotype) as a major contributor, alongside CYP3A4 (the liver’s highest-volume drug-metabolizing enzyme), CYP1A2 (a liver enzyme that clears caffeine and is induced by tobacco smoke), and CYP2E1 (a liver enzyme that processes alcohol and several small solvents). The dominant urinary metabolite is 2-oxo-3-hydroxy-LSD, which is pharmacologically inactive and is the analyte used in forensic testing.

Historical Context & Evolution

LSD was first synthesized by Albert Hofmann at Sandoz Laboratories in Basel in November 1938, as the twenty-fifth compound in a series of lysergic acid derivatives — hence the label LSD-25. The original intent was pharmaceutical and entirely conventional: ergot alkaloids were already established as circulatory and uterine agents, and Sandoz was screening derivatives as analeptics (circulatory and respiratory stimulants). The compound was set aside for five years as unremarkable. Hofmann resynthesized it in April 1943, absorbed a trace amount, and three days later took 250 micrograms deliberately, which he had estimated as a threshold dose and which is in fact a large one.

Sandoz marketed the compound from 1947 as Delysid and distributed it without charge to psychiatric researchers, framing it two ways: as a tool for psychiatrists to experience a model psychosis, and as an adjunct to psychotherapy. Between 1950 and 1965 roughly 1,000 papers were published and an estimated 40,000 patients received it. The findings of that literature, rather than its reception, are what matter for present purposes.

• The alcoholism work produced measurable results. Six randomized controlled trials conducted between 1966 and 1970 in Canada and the United States, covering 536 participants, compared a single high dose against low-dose or non-drug controls within existing treatment programs. Pooled by Krebs and Johansen in 2012, they show an odds ratio (a multiplier on the chance of an outcome relative to the comparison group) of 1.96, with a 95% confidence interval (the range in which the true value most likely lies) of 1.36 to 2.84, for improvement in alcohol misuse at first follow-up, with zero measurable between-trial heterogeneity. The effect attenuated by six months and was no longer significant at twelve.

• The end-of-life work produced consistent case series. Eric Kast’s studies at Chicago Medical School through the 1960s reported that a single dose reduced pain and death anxiety in terminally ill patients for longer than the analgesia lasted; Stanislav Grof’s Spring Grove work reported similar findings in a larger series.

• Two parallel treatment philosophies emerged. The European “psycholytic” approach used repeated low-to-moderate doses to loosen defenses within ongoing psychotherapy. The North American “psychedelic” approach used a single overwhelming dose to induce a peak experience. Modern trials descend almost entirely from the second.

Against this, the record contains serious problems that were also real: trials were rarely blinded in any meaningful sense, control conditions were weak, outcome measures were inconsistent, and a substantial fraction of the work was ethically indefensible — most notably the CIA’s MKUltra programme, which administered the compound covertly and non-consensually.

The collapse of the field between 1966 and 1970 was driven by a mixture of these methodological and ethical failures, the compound’s escape into unsupervised recreational use, emergency-room presentations, and a political reaction in which Sandoz withdrew Delysid in 1966 and the United States placed LSD in Schedule I under the Controlled Substances Act of 1970. That schedule assignment asserts no accepted medical use and a high abuse potential — a claim that was contested at the time and remains contested now, and which functioned as a research prohibition for three decades regardless of its accuracy.

The revival did not overturn the old findings so much as re-run them under modern conditions. Peter Gasser’s 2014 Swiss trial in anxiety associated with life-threatening illness was the first controlled LSD study in over forty years. The Basel group under Matthias Liechti subsequently ran dose-response and mechanism studies in healthy volunteers, then a randomized placebo-controlled phase 2 trial in anxiety published in 2023. Switzerland has operated a limited-medical-use programme since 2014 permitting supervised administration under individual exemption. In 2024 the United States Food and Drug Administration granted Breakthrough Therapy designation to a standardized preparation for generalized anxiety disorder, and a phase 2b dose-finding trial was published in 2025.

What changed on each side is worth stating plainly. Evidence strengthening the case: blinded dose-response data now exist, adverse events are systematically catalogued, and the anxiety signal has replicated across independent groups. Evidence weakening it: network meta-analysis that corrects for the unusually low placebo response in psychedelic trials removes LSD’s advantage for depressive symptoms; controlled tests of low-dose regimens have repeatedly failed to beat placebo; and functional unblinding remains unsolved, since participants almost always know which arm they are in. The current position is not a settled verdict in either direction.

The organizations that shaped both the decline and the revival have interests of their own. Advocacy bodies such as the Multidisciplinary Association for Psychedelic Studies and Drug Science derive their funding, membership, and institutional relevance from psychedelics being reclassified and commercialized; drug-control agencies derive budget, staffing, and statutory authority from the prohibition being maintained. Neither side’s position on this compound should be read as a disinterested reading of the data.

Expected Benefits

The evidence base has an unusual shape: a small number of well-conducted modern randomized controlled trials (RCTs — studies in which participants are assigned to treatment or control at random), a large but methodologically weak historical literature, and a very large volume of uncontrolled self-report about low-dose use. Benefits are graded accordingly. Grades reflect what the evidence supports for a screened, healthy, motivated adult in a supervised setting, not what a population-level rollout would produce.

Where trials of the standardized preparation MM120 are cited below, the sponsor is a commercial developer of that preparation (Mind Medicine, now operating as Definium Therapeutics), which holds a direct financial interest in favorable results; this conflict is noted again in the Conclusion.

High 🟩 🟩 🟩

Reduction of Long-Standing Anxiety After One or Two Supervised Sessions

This is the best-supported effect and the only one with two independent modern randomized controlled trials pointing the same way. In a commercially sponsored phase 2b dose-finding trial in 198 adults with moderate-to-severe generalized anxiety disorder (a condition of persistent, excessive worry across many domains), a single dose produced a dose-dependent fall in anxiety scores that persisted at four weeks. In an investigator-initiated Swiss crossover trial in 42 patients with anxiety, with and without a life-threatening illness, two doses of 200 micrograms produced reductions that were still present sixteen weeks after the last session. The proposed mechanism is a durable loosening of rigid self-referential thought patterns following the acute network disruption; the size of the acute mystical-type experience correlates with the long-term outcome. The main limitation is functional unblinding — participants can tell which arm they are in — which likely inflates the apparent effect to an unknown degree.

Magnitude: −5.0 points (95% confidence interval −9.6 to −0.4) on the Hamilton Anxiety Rating Scale at 100 micrograms and −6.0 points (95% confidence interval −9.8 to −2.0) at 200 micrograms versus placebo at four weeks, against a minimal clinically important difference of 2.5 points; −16.2 points on the State-Trait Anxiety Inventory global score at sixteen weeks in the Swiss trial, a large effect (Cohen’s d, a standardized measure of effect size, of −1.18).

Reduction in Alcohol Misuse After a Single Session

Six randomized controlled trials from the 1960s and early 1970s, pooled in 2012, consistently show that a single high dose added to an existing alcohol treatment programme improves drinking outcomes at first follow-up. The pooled effect is significant, the confidence interval excludes no effect, and between-trial heterogeneity is zero, which is unusual for a historical literature. The proposed mechanism is the same as for anxiety: a single strongly meaningful experience that changes the person’s relationship to the behavior rather than blocking a craving pathway. The limitations are substantial and must be weighed: blinding was poor, the trials predate modern outcome standards, and the benefit had faded to non-significance by twelve months. A modern replication in 128 participants is underway but has not reported.

Magnitude: odds ratio 1.96 (95% confidence interval 1.36 to 2.84) for improvement in alcohol misuse at first follow-up across 536 participants; equivalent to roughly a 15 percentage-point absolute increase in the proportion improved. Effect not significant at twelve months.

Medium 🟩 🟩

Sustained Increases in Well-Being, Openness, and Life Satisfaction in Healthy Adults

Modern controlled trials in healthy volunteers, pooled across five randomized trials in 132 participants, show reliable acute elevation of mood ratings with a moderate-to-large effect at 100 and 200 micrograms. Follow-up work from the Basel group reports that increases in the personality trait of openness and in self-rated well-being remain measurable at twelve months after one or two sessions, and that the magnitude of the acute increase in global brain entropy predicts the openness change. This is the domain most relevant to a healthy longevity-oriented adult rather than a patient. The nuance is that these are small samples of self-selected volunteers, the measures are self-report, and personality-change findings across the psychedelic literature have been questioned on the grounds that expectancy alone can move openness scales.

Magnitude: moderate-to-large acute effects on mood rating scales at 100 to 200 micrograms; openness increases of roughly 4 to 8 percentile points sustained at twelve months in follow-up cohorts.

Reduction of Depressive Symptoms ⚠️ Conflicted

In the Swiss anxiety trial, comorbid depression fell substantially and durably alongside anxiety, on both clinician-rated and self-rated scales. A separate Swiss randomized trial in 61 patients whose primary diagnosis was moderate-to-severe major depression found two high doses superior to two low doses on the clinician-rated depression scale, although the difference no longer reached significance once baseline severity was adjusted for. Both conflict with the best available comparative analysis: a Bayesian network meta-analysis (a method that ranks treatments against one another by pooling trials, including treatments never compared head to head) that pooled psychedelic and antidepressant trials found that LSD did not separate from placebo for depressive symptoms once the placebo response was calibrated to antidepressant-trial norms, whereas high-dose psilocybin did. The most likely reasons for the discrepancy are that the depression-primary trial was small and used a low active dose rather than an inert placebo as its comparator, and that the unusually low placebo response in psychedelic trials inflates within-field comparisons. Phase 3 depression trials are underway and will settle this.

Magnitude: −7.0 points on the 21-item Hamilton Depression Rating Scale (Cohen’s d −1.1) and −6.1 points on the Beck Depression Inventory (Cohen’s d −0.72) at sixteen weeks in the anxiety trial; −9.2 points (95% confidence interval −17.1 to −1.3) on the clinician-rated Inventory of Depressive Symptomatology for high versus low dose in the depression trial, losing significance after adjustment for baseline severity; no significant separation from placebo in the calibrated network meta-analysis.

Reduction in Existential Distress in Serious Illness

Across the 1960s case series, the 2014 Swiss trial in 12 patients with anxiety related to life-threatening disease, and the anxiety subgroup of the 2023 trial, a single or double supervised session reduces death anxiety, demoralization (a persistent loss of meaning, hope, and sense of purpose), and the psychological suffering component of pain, with benefit outlasting any pharmacological presence. The proposed mechanism is the mystical-type experience and the reframing of self-continuity it produces. Evidence is graded Medium rather than High because the modern samples are very small, the outcome is inherently subjective, and blinding in this population is essentially impossible.

Magnitude: State-Trait Anxiety Inventory reductions at two months in the 2014 trial of a size equivalent to a Cohen’s d of 1.1 for trait anxiety and 1.2 for state anxiety versus a 20-microgram active control, both large effects, sustained at twelve months; the effect has not been separately quantified in a trial powered for this population.

Low 🟩

Reduction in Cluster Headache Attack Frequency

Cluster headache — attacks of extremely severe one-sided head pain occurring in bouts — has a long-standing underground practice of using sub-hallucinogenic doses of LSD or related ergot compounds to interrupt a bout. Support comes from retrospective survey series and open-label reports rather than controlled data, though the mechanism is plausible given that ergot derivatives are established anti-migraine agents acting on the same receptor family. Two phase 2 randomized trials are running. Until they report, this is a promising but unconfirmed indication.

Magnitude: Not quantified in available studies.

Acute Increase in Pain Tolerance

A controlled crossover study in healthy volunteers found that 20 micrograms — a dose below the threshold for clear perceptual change — raised cold-pressor pain tolerance and lowered subjective painfulness, with the effect still measurable five hours later. The proposed mechanism is 5-HT2A-mediated modulation of pain affect rather than pain transmission. It is a single small study without clinical replication in a pain population.

Magnitude: roughly 20 percent increase in cold-pressor tolerance time at 20 micrograms versus placebo in a single small crossover trial.

Modest Increase in Sleep Duration Following Low-Dose Administration ⚠️ Conflicted

A randomized controlled trial of repeated low doses in healthy adults found that total sleep time increased on the night following a dose, without a change in sleep architecture, measured objectively rather than by self-report. This conflicts with the frequent self-reported complaint of insomnia on dosing days, and with the raised blood pressure and arousal that the microdosing safety literature documents. The likely reconciliation is that a dose taken in the morning produces a rebound toward more sleep that night, whereas a dose taken later disrupts it — a timing effect rather than a contradiction.

Magnitude: approximately 20 to 25 additional minutes of total sleep on the night after a morning dose, with no change in the proportion of deep or rapid-eye-movement sleep.

Improvement in Mood and Focus From Scheduled Low Doses ⚠️ Conflicted

This is the most popular use among health-optimizing adults and the least well-supported. Uncontrolled surveys report large benefits to mood, creativity, and focus. Controlled trials do not reproduce them: a home-administered randomized trial of repeated low doses found acute mood elevation on dosing days but no accumulation of benefit; a large self-blinding citizen-science study found improvements in both real and placebo arms with no difference between them; and a meta-analysis of microdosing effects on cognition found no reliable cognitive enhancement. The most parsimonious explanation for the gap is expectancy combined with the self-selection of people already inclined to report benefit. A grade of Low reflects that a small acute mood effect is genuinely demonstrated while the sustained benefit that motivates the practice is not.

Magnitude: small acute elevation of mood ratings on dosing days only, of a size comparable to the placebo response in the same trials; no detectable cognitive or sustained mood benefit versus placebo.

Speculative 🟨

Anti-Inflammatory Signalling Through 5-HT2A

Activation of 5-HT2A receptors at very low concentrations suppresses tumour necrosis factor-α-mediated inflammatory signalling in vascular and immune tissue in preclinical models, an effect described for the related compound (R)-DOI at doses far below those producing perceptual change. Since chronic low-grade inflammation is a plausible driver of age-related disease, this has been proposed as a longevity-relevant mechanism for low-dose psychedelics. No controlled human study has measured inflammatory markers after LSD as a primary endpoint, so the basis here is mechanistic and preclinical only.

Preservation of Cognitive Function and Mood in Later Life

Cross-sectional analyses of older adults report better executive function and fewer depressive symptoms among those with a history of psychedelic use, and a prospective cohort of guided psychedelic group sessions reported improved well-being in older participants. Separately, a 2025 laboratory study reported that psilocin, the active metabolite of psilocybin, extended replicative lifespan in human cells and improved survival in aged mice. None of this is LSD-specific, none is randomized, and the observational associations are fully explicable by the healthy-user effect. The basis is mechanistic reasoning and uncontrolled observation only.

Enhanced Response to Psychological Interventions Delivered Afterwards

The “critical period” hypothesis holds that 5-HT2A agonists reopen a window of heightened social and behavioral learning for days to weeks after a dose, which would mean the compound’s main value is as an amplifier of whatever psychological work follows rather than as a treatment in itself. The evidence is rodent work on social reward learning plus indirect human observations that integration quality predicts outcome. No controlled human trial has manipulated the post-session intervention while holding the dose constant, so this remains mechanistic.

Benefit-Modifying Factors

• HTR2A receptor variants: the gene encoding the 5-HT2A receptor carries common variants (including the rs6311 and rs6313 polymorphisms) that alter receptor density in cortex. These have been linked to differences in the intensity of the acute response to psychedelics, and plausibly to how much therapeutic signal a given dose produces, though no trial has stratified outcomes by genotype.

• CYP2D6 metabolizer status: CYP2D6 is a liver enzyme with genetically determined activity ranging from absent to greatly increased. Because it contributes materially to LSD clearance, poor metabolizers should experience a longer and stronger response from the same dose, and ultra-rapid metabolizers a shorter and weaker one. This is the single most plausible pharmacogenetic driver of the wide inter-individual variability that clinicians report.

• Baseline serotonergic drug exposure: ongoing treatment with a selective serotonin reuptake inhibitor (SSRI — the most common class of antidepressant, which raises serotonin availability in the synapse) downregulates 5-HT2A receptors over weeks, and current or recent SSRI use is the best-documented predictor of a blunted or absent response. Baseline exposure, not dose, is often the reason a session produces nothing.

• Baseline severity of the target symptom: the anxiety trials show the largest reductions in those starting with the highest scores, which is partly regression to the mean (the tendency for unusually extreme starting values to drift back toward average on retesting) but also reflects a floor effect — a healthy adult with normal anxiety has limited room to improve, so the benefit profile for an optimizing adult skews toward well-being and openness rather than symptom relief.

• Trait absorption and openness: pre-existing capacity for absorbed, imaginative states predicts the intensity of the acute experience, and the intensity of the acute experience predicts the durable outcome. This is the most consistently replicated psychological moderator across the psychedelic literature.

• Sex-based differences: women show higher plasma concentrations per unit body weight and report somewhat more intense acute effects at fixed doses, consistent with body-composition differences rather than a distinct pharmacology. No trial has demonstrated a sex difference in therapeutic outcome, and the 2025 phase 2b trial was 57 percent female with no reported interaction between sex and response.

• Pre-existing health conditions: the presence of a comorbid depressive disorder alongside anxiety is associated with larger absolute improvements across both domains. Conversely, an untreated anxiety disorder makes an acutely difficult session more likely, which can undercut the benefit if the experience is not contained.

• Age-related considerations: the modern trials have enrolled adults up to 74 years, and no age-related decline in efficacy has been reported. Cortical 5-HT2A receptor density falls with age, which predicts a somewhat blunted response in older adults at a fixed dose, and cross-sectional data in older users show benefit rather than harm. The practical constraint at the older end is cardiovascular tolerance of the acute blood-pressure rise rather than diminished psychological effect.

Potential Risks & Side Effects

The safety profile splits sharply by setting. In screened participants under supervision, the physical risks are modest and the psychological risks are largely time-limited. Outside that container, with an unverified compound and no screening, the risk profile is materially different and is not what the trial data describe. Grades below refer to the evidence for the risk existing, not to its severity.

High 🟥 🟥 🟥

Perceptual Disturbance and Loss of Ordinary Functioning for 8 to 12 Hours

This is not an adverse event so much as the intended effect, but it is the dominant practical risk. In the 2025 dose-finding trial, visual perceptual changes — illusions, pseudo-hallucinations, and frank visual hallucinations — occurred in 92.5 percent of participants at 100 micrograms and in every participant at 200 micrograms. Judgment, motor coordination, and the ability to assess risk are impaired throughout. There is no antidote that reliably shortens the experience, though benzodiazepines (a class of fast-acting sedative and anti-anxiety medicines) blunt distress. Any activity requiring competence — driving, work, childcare, financial decisions — is precluded for the day and, for many, the following morning.

Magnitude: perceptual changes in 92.5 percent at 100 micrograms and 100 percent at 200 micrograms versus 10.3 percent on placebo; full duration 8 to 11 hours with residual effects for a further 12 to 24 hours.

Acute Psychological Distress During the Session

Intense anxiety, fear of losing one’s mind, paranoia, and the sense of dying are common transient features at full doses, and they are the events that most often require intervention. In the Swiss anxiety trial, 19 percent of patients reported transient acute untoward effects, and one participant (2 percent) had a serious adverse event of acute transient anxiety. The mechanism is straightforward: 5-HT2A activation removes the ordinary constraints on perception and self-model, and how that is experienced depends heavily on preparation, setting, and the presence of a trained monitor. Severity is almost always self-limiting within the session, and difficult passages that are worked through are associated with better rather than worse outcomes. Without supervision, the same states are the main driver of emergency presentations.

Magnitude: transient acute untoward effects in approximately 19 percent of patients; serious adverse events in approximately 2 percent in supervised trials, and in approximately 4 percent of participants with pre-existing neuropsychiatric disorders across 3,504 participants in a meta-analysis of classic psychedelic trials, versus none in healthy participants.

Acute Cardiovascular and Autonomic Stimulation

LSD raises blood pressure, heart rate, and body temperature, and produces pupil dilation, tremor, and nausea, through combined serotonergic and adrenergic action. In healthy screened volunteers this is well tolerated and self-limiting. In a person with untreated hypertension, unstable coronary disease, an aortic aneurysm (a bulge in the wall of the body’s main artery), or an arrhythmia (an abnormal heart rhythm), a several-hour pressor (blood-pressure-raising) load with no ability to communicate symptoms reliably is a genuine hazard, and these conditions are exclusion criteria in every modern trial for that reason.

Magnitude: systolic blood pressure rise of approximately 15 to 25 mmHg and diastolic rise of approximately 10 to 15 mmHg, heart rate rise of approximately 10 to 20 beats per minute, and body temperature rise of up to 0.5 °C, peaking at 1 to 3 hours; nausea in 40 percent at 100 micrograms and 60 percent at 200 micrograms; headache in 27 to 35 percent.

Rapid Tolerance With Repeated Dosing

Tolerance to the subjective effects develops within two to three consecutive daily doses and is near-complete by the fourth, driven by 5-HT2A receptor downregulation, and it resolves over roughly a week of abstinence. This is among the most consistently replicated pharmacological findings for the compound, established in controlled human dosing studies from the 1950s onward and reproduced in modern work. It also cross-generalizes to psilocybin and mescaline. The practical consequence is that dose escalation to chase an effect is futile and increases cardiovascular exposure without increasing benefit.

Magnitude: near-complete loss of subjective effect after three to four consecutive daily doses; full recovery of sensitivity within approximately 5 to 7 days of abstinence.

Medium 🟥 🟥

Precipitation or Worsening of Psychosis and Mania

Classic psychedelics can trigger psychotic or manic episodes, and the risk concentrates almost entirely in people with a personal or first-degree family history of schizophrenia or bipolar disorder — which is why every trial screens for it. A 2025 meta-analysis of human studies put the incidence of psychedelic-induced psychosis at 0.002 percent in population studies, 0.2 percent in uncontrolled trials, and 0.6 percent in randomized controlled trials; among people with pre-existing schizophrenia in uncontrolled trials, 3.8 percent developed long-lasting psychotic symptoms, and 13.1 percent of those with a psychedelic-induced psychosis later met criteria for schizophrenia. Systematic review of hypomania (a milder, shorter episode of abnormally elevated mood, drive, and reduced need for sleep) and mania after psychedelics identifies the same concentration of risk in those with bipolar-spectrum vulnerability. The events are rare in absolute terms but are the most consequential and least reversible harm documented.

Magnitude: psychosis incidence 0.002 percent in population studies, 0.2 percent in uncontrolled trials, 0.6 percent in randomized controlled trials; 3.8 percent developing long-lasting psychotic symptoms among participants with pre-existing schizophrenia.

Hallucinogen Persisting Perception Disorder

Hallucinogen persisting perception disorder (HPPD) is the persistence of visual phenomena — trailing images, halos, visual snow, afterimages — for months or years after exposure, sometimes with associated anxiety about the symptoms. The mechanism is unclear; disinhibition of visual cortical processing is the leading hypothesis. It is well documented in case series going back decades in recreational populations, particularly after frequent or high-dose use, and it appears more often in people with pre-existing anxiety or attentional sensitivity. Notably, no cases have been reported following high-dose administration in contemporary clinical trials across 3,504 participants, and published population estimates vary by more than an order of magnitude. Severity ranges from a curiosity to genuinely disabling, and there is no established treatment, though symptoms often attenuate over years.

Magnitude: zero cases across 3,504 participants in contemporary clinical trials of high-dose classic psychedelics; prevalence in recreational populations is not reliably established, with published estimates varying by more than an order of magnitude depending on the case definition used.

Blood Pressure Elevation and Anxiety From Repeated Low-Dose Use

The systematic review of microdosing harms across 31 studies identifies raised blood pressure, anxiety, and cognitive impairment as the recurring dose-dependent signals, and notes that most of the underlying studies are short. Because the practice involves repeated exposure over months, a modest pressor effect that would be trivial once becomes a chronic exposure of unknown consequence, and the compounding cardiovascular effect has not been studied over the relevant timescale. This is the most concrete near-term risk of the practice that health-optimizing adults are most likely to adopt.

Magnitude: blood pressure increases of a few mmHg reported consistently across laboratory microdosing studies; long-term cumulative effect not quantified in available studies.

Prolonged Post-Session Destabilization

A minority of people experience days to weeks of low mood, anxiety, derealization (a persisting sense that surroundings are unreal or dreamlike), or difficulty reintegrating after a session, distinct from the usual positive afterglow. It appears more likely after unprepared, unsupported, or very high-dose sessions and in people with unresolved trauma. In trials it is uncommon and self-limiting because integration sessions are built into the protocol; outside trials it is the most common reason people seek help afterwards. Cognitive flexibility has been shown to be measurably reduced the day after a session even while memory and verbal fluency improve, which fits the clinical picture of a genuine but temporary destabilization.

Magnitude: measurable next-day reduction in cognitive flexibility alongside improved episodic memory and verbal fluency; incidence of clinically significant prolonged destabilization not quantified in available studies.

Low 🟥

Valvular Heart Disease From Sustained 5-HT2B Activation

LSD binds the 5-HT2B receptor with high affinity and produces β-arrestin-biased signalling in valvular interstitial cells — the same receptor and the same signalling route through which fenfluramine, pergolide, cabergoline, and methysergide caused valve fibrosis and were withdrawn or restricted. A 2026 systematic review of seventeen studies found in vitro and structural evidence that LSD engages this pathway and in vivo evidence that sustained serotonergic stimulation causes valvulopathy (disease of the heart valves), but no reported clinical case of LSD-induced valve disease in humans. The risk is therefore mechanistically well-grounded and clinically unobserved. It is close to irrelevant for one or two supervised sessions, since the offending drugs required daily exposure for months to years, and it is the single most important open question for anyone contemplating scheduled low-dose use over years. The class precedent is that daily exposure to other 5-HT2B agonists produced clinically significant regurgitation (backward leakage of blood through a valve that no longer closes properly) in a substantial minority of users, while no human case of LSD-associated valve disease has been reported to date.

Magnitude: Not quantified in available studies.

Accidental Injury and Behavioral Harm While Impaired

Falls, traffic incidents, and consequential decisions made in an altered state account for a large share of documented LSD-related harm, and essentially all of it occurs outside supervised settings. There is no pharmacological toxicity involved; the mechanism is impaired judgment and altered perception for a prolonged period. Severity ranges from trivial to fatal, and it is fully preventable by the setting controls that trials use as standard. No death attributable to the compound itself has occurred in any supervised trial, and there is no reliably documented human fatality from LSD toxicity alone.

Magnitude: Not quantified in available studies.

Adulteration and Misidentification of Unregulated Material

Blotter and liquid sold as LSD is frequently something else, most consequentially the NBOMe series (N-methoxybenzyl phenethylamines, potent synthetic 5-HT2A agonists sold as LSD substitutes), which unlike LSD have a documented lethal toxicity through hyperthermia, seizures, and vasoconstriction. Deaths attributed to “LSD” in the literature are overwhelmingly NBOMe cases. This is a supply risk rather than a pharmacological one, but it is the most likely mechanism by which a person is seriously harmed in practice. Multiple fatalities from NBOMe compounds sold as LSD are confirmed in the forensic literature, versus none attributable to LSD itself.

Magnitude: Not quantified in available studies.

Speculative 🟨

Cumulative Cardiac Fibrosis Below the Threshold of Clinical Valve Disease

If the 5-HT2B pathway is engaged at low-dose concentrations, subclinical valvular thickening could accumulate over years of scheduled use without producing symptoms or a murmur, and would only be visible on serial imaging. No study has performed echocardiography before and after a multi-year low-dose regimen, so there is no data of any kind on this; the basis is purely the extrapolation of a known drug-class mechanism to a dosing pattern that has never been studied.

Unfavorable Interaction With Age-Related Serotonergic Decline

Cortical 5-HT2A receptor density declines substantially across the adult lifespan. Whether repeated agonist exposure accelerates that decline, protects against it, or does nothing is unknown, and the three possibilities have opposite implications for an older adult using the compound over years. The basis is mechanistic reasoning from receptor-downregulation kinetics only, with no human longitudinal data.

Effects on Immune and Inflammatory Aging

The same 5-HT2A anti-inflammatory signalling proposed as a benefit could, under chronic stimulation, produce receptor desensitization or unwanted immunomodulation. No human study has measured immune or inflammatory endpoints after repeated LSD exposure, so both the hoped-for benefit and this mirror-image risk rest on the same preclinical signalling data and neither has been tested.

Risk-Modifying Factors

• Personal or family history of psychotic or bipolar illness: this is the dominant risk modifier and the reason it is an absolute exclusion in every trial. A first-degree relative with schizophrenia or bipolar I disorder moves an individual from the 0.6 percent trial-setting psychosis incidence into a materially higher risk band that has not been separately quantified because such individuals are never enrolled.

• CYP2D6 poor metabolizer genotype: reduced clearance means a longer and more intense exposure from a standard dose, extending both the duration of cardiovascular load and the window of psychological vulnerability. Genotype-guided dose reduction is not standard practice but is mechanistically well-founded.

• HTR2A receptor variants: variants that increase cortical 5-HT2A density plausibly increase both the intensity of the acute experience and the likelihood of an overwhelming one at a given dose, though no trial has stratified adverse events by genotype.

• Baseline blood pressure and cardiac status: an untreated systolic pressure above 140 mmHg, known coronary artery disease, an arrhythmia, a cardiomyopathy (disease of the heart muscle itself), or existing valvular regurgitation each convert the routine several-hour pressor response into a meaningful hazard. Baseline echocardiographic valve status is the specific modifier for anyone considering repeated exposure, given the 5-HT2B mechanism.

• Current serotonergic and psychiatric medication: ongoing SSRI, serotonin-norepinephrine reuptake inhibitor (SNRI — an antidepressant class that raises both serotonin and noradrenaline availability), or monoamine oxidase inhibitor (MAOI — an older antidepressant class that blocks the enzyme breaking down serotonin and related messengers) treatment, and particularly lithium, alter the risk profile substantially — lithium in the direction of seizures and prolonged severe reactions rather than merely a blunted response.

• Sex-based differences: women reach higher plasma concentrations at a fixed absolute dose, which implies a somewhat greater acute autonomic and psychological load per milligram of body weight; no sex difference in serious adverse event rates has been demonstrated in the trial literature, and the 2025 trial’s majority-female sample reported none.

• Pre-existing anxiety sensitivity or trauma history: high anxiety sensitivity predicts both a more difficult acute experience and a higher likelihood of prolonged post-session destabilization, and unprocessed trauma is the most common precipitant of a session that ends badly without adequate support. Pre-existing anxiety also appears more often in the histories of people who develop persisting perceptual symptoms.

• Age-related considerations: older adults carry more undiagnosed cardiovascular disease, take more interacting medications, and have lower physiological reserve for a sustained pressor response, which shifts the risk balance even though the psychological response is not obviously worse. Reduced hepatic clearance with age also lengthens exposure. Beyond roughly 65, the case for a full cardiac workup before a full-dose session is substantially stronger than the psychological risk profile alone would suggest.

Key Interactions & Contraindications

• Lithium — absolute contraindication. Case series consistently report seizures, prolonged psychosis, and severely dysphoric (profoundly unpleasant, distressed, and agitated) reactions when psychedelics are combined with lithium, and this is the single most dangerous documented interaction. Mitigation is avoidance, not dose adjustment; if lithium is being discontinued for another reason, several weeks of washout under psychiatric supervision would be required before any exposure.

• Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors (fluoxetine, sertraline, escitalopram, venlafaxine, duloxetine) — caution, response attenuation. Chronic use downregulates 5-HT2A receptors and markedly blunts or abolishes the acute effect. Clinical consequence is treatment failure rather than harm. Mitigation is a supervised taper and washout, typically 2 weeks for most agents and 4 to 6 weeks for fluoxetine because of its long half-life, which itself carries a relapse risk that has to be weighed.

• Monoamine oxidase inhibitors (phenelzine, tranylcypromine, moclobemide, and the antibiotic linezolid) — absolute contraindication. Unpredictable potentiation and serotonin-toxicity risk. Clinical consequence ranges from prolonged, greatly intensified effects to serotonin syndrome (a potentially fatal state of agitation, fever, rigidity, and autonomic instability). Mitigation is avoidance with a minimum 2-week washout after stopping the inhibitor.

• Tricyclic antidepressants (an older antidepressant class named for its three-ring chemical structure: amitriptyline, imipramine, clomipramine) — caution. Reported to potentiate the acute response substantially. Clinical consequence is an unexpectedly overwhelming experience at a normally moderate dose. Mitigation is dose reduction of the psychedelic or avoidance.

• Atypical and typical antipsychotics (medicines used to treat psychosis and mania: risperidone, olanzapine, haloperidol) — interaction, therapeutic and blocking. These block 5-HT2A and dopamine D2 receptors and will abolish or truncate the effect. Clinical consequence outside of a rescue context is treatment failure. This is also the mitigation route in reverse: a 5-HT2A antagonist is the pharmacological means of terminating an unmanageable session, though benzodiazepines are preferred first-line because antipsychotics can worsen dysphoria.

• CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion, quinidine, terbinafine) — caution. These reduce clearance and prolong exposure. Clinical consequence is a longer and stronger response than the dose predicts, extending the cardiovascular load. Mitigation is a downward dose adjustment or timing separation of at least five half-lives of the inhibitor.

• CYP3A4 inhibitors and inducers (ketoconazole, ritonavir, clarithromycin, grapefruit juice as inhibitors; carbamazepine, rifampicin, St John’s wort as inducers) — caution. Inhibitors prolong exposure, inducers shorten and weaken it. Mitigation is separation in time and, for regular users of an inhibitor, downward dose adjustment.

• Over-the-counter serotonergic agents (dextromethorphan in cough preparations, chlorpheniramine, and high-dose diphenhydramine) — caution. Additive serotonergic and anticholinergic (blocking acetylcholine, the messenger that supports memory, alertness, and gut and bladder function) load, with dextromethorphan in particular contributing to serotonin toxicity risk and to confusional states. Mitigation is separation by at least 24 hours around a session.

• Stimulants, prescribed or otherwise (methylphenidate, amphetamine salts, caffeine at high intake, cocaine) — caution. Additive cardiovascular load and additive anxiety. Clinical consequence is a higher pressor peak and a substantially greater chance of an acutely distressing experience. Mitigation is omission of stimulants on the day of a session and moderation of caffeine.

• Supplement interactions with additive serotonergic effect: St John’s wort (a monoamine oxidase-inhibiting and reuptake-inhibiting botanical), 5-HTP and L-Tryptophan (direct serotonin precursors), S-adenosylmethionine, and high-dose tryptophan-containing protein supplements all add serotonergic tone. Severity is caution to avoidance, and the clinical consequence is potentiation with serotonin-toxicity risk. Mitigation is stopping serotonergic supplements at least 2 weeks before a session.

• Supplements that add cardiovascular load — caution. Yohimbine, synephrine, high-dose caffeine, and ephedra-containing preparations each raise blood pressure and heart rate on their own. Combined with a several-hour pressor response, the clinical consequence is a materially higher peak pressure. Mitigation is discontinuation for at least 48 hours around a session.

• Supplements and drugs that blunt the response — monitor. Magnesium at high doses, exogenous melatonin taken close to dosing, and any 5-HT2A-antagonizing agent (including some antihistamines and trazodone) reduce the effect. Clinical consequence is a wasted session rather than harm. Mitigation is omission of these agents on the day of a session.

• Cannabis — caution. Frequently combined recreationally, and consistently reported to intensify and destabilize the experience unpredictably, with an increased incidence of acute anxiety and paranoia. Mitigation is abstinence for at least 24 hours before and during a session.

• Populations who should avoid the intervention entirely:

  • Anyone with a personal history of schizophrenia, schizoaffective disorder, or bipolar I disorder, or a first-degree relative with any of these.
  • Anyone with a current psychotic or manic episode, or active suicidal ideation with intent.
  • Anyone with uncontrolled hypertension, defined as systolic above 140 mmHg or diastolic above 90 mmHg on repeated measurement, or a hypertensive emergency history.
  • Anyone with unstable coronary artery disease, a myocardial infarction within the last 6 to 12 months, decompensated heart failure of New York Heart Association Class III or IV, or a clinically significant arrhythmia.
  • Anyone with existing moderate or greater valvular regurgitation, or with a history of exposure to another 5-HT2B agonist such as fenfluramine, pergolide, or long-term ergot-derived migraine medication.
  • Anyone with an unrepaired aortic aneurysm or a history of aortic dissection (a tear in the wall of that artery).
  • Anyone with a seizure disorder, given the reported lowering of seizure threshold, particularly in combination with lithium or tricyclics.
  • Anyone with severe hepatic impairment of Child-Pugh Class B or C, given hepatic clearance.
  • Pregnancy and breastfeeding, on the basis of absent safety data rather than demonstrated harm.
  • Anyone taking lithium or a monoamine oxidase inhibitor.
  • Anyone unable to arrange a supervised, protected 12-hour window with a sober attendant.

Risk Mitigation Strategies

• Structured psychiatric and family-history screening before any exposure: a documented review for personal and first-degree-family history of schizophrenia, schizoaffective disorder, and bipolar I disorder, since this single filter is what separates the 0.6 percent psychosis incidence seen in trials from the substantially higher rate among people with pre-existing psychotic vulnerability. This mitigates precipitation of psychosis and mania, the least reversible documented harm.

• Cardiovascular clearance proportionate to the planned exposure: blood pressure measured on at least two occasions with a target below 140/90 mmHg before a full dose, a 12-lead electrocardiogram in anyone over 50 or with any cardiac symptom, and a transthoracic echocardiogram before beginning any regimen intended to run longer than 6 months. This mitigates the acute pressor risk and establishes the baseline against which the 5-HT2B valvular concern could ever be detected.

• Low starting dose with stepwise escalation across separate sessions: protocols in the phase 2b programme showed clinically meaningful separation from placebo only at 100 and 200 micrograms, but a first exposure at 25 to 50 micrograms establishes individual sensitivity, metabolizer status, and cardiovascular response before committing to a full dose. Escalation is between sessions separated by at least 2 weeks, never within a session. This mitigates the risk of an overwhelming first experience and of an unexpectedly large pressor response in a poor metabolizer.

• Mandatory washout of interacting medications and supplements: 2 weeks off most selective serotonin reuptake inhibitors and 4 to 6 weeks off fluoxetine to restore receptor sensitivity, 2 weeks off monoamine oxidase inhibitors and serotonergic supplements to avoid serotonin toxicity, 48 hours off stimulant and pressor supplements, and complete avoidance of any session while on lithium. This mitigates both treatment failure and the seizure and serotonin-syndrome interactions.

• A trained, sober monitor present for the full duration: one attendant who remains present and does not take the compound, with an agreed plan for the acutely distressing passages, mitigates essentially the entire category of accidental injury and converts the majority of difficult experiences from an emergency into a manageable part of the session.

• A pharmacological rescue plan agreed in advance: an oral benzodiazepine such as lorazepam 1 to 2 mg available to the monitor for unmanageable acute anxiety, with a 5-HT2A antagonist reserved for a clinical setting. This mitigates acute psychological distress and reduces the likelihood that a difficult passage becomes a prolonged destabilization.

• A protected 24- to 36-hour window with no obligations: the full 8 to 11 hours of effect plus a following day free of driving, work, and consequential decisions, since next-day cognitive flexibility is measurably reduced. This mitigates accidental injury and impaired-judgment harm during the residual period.

• Analytical verification of any unregulated material: reagent testing (Ehrlich and Hofmann reagents) as a minimum and quantitative laboratory analysis where a drug-checking service exists, since the NBOMe compounds sold as LSD are the only realistic route to a fatal outcome. Blotter that tastes bitter is a practical warning sign, as LSD itself is tasteless at active doses. This mitigates the adulteration risk directly.

• Frequency ceiling and enforced spacing: a minimum of 2 weeks between full-dose sessions and, for low-dose regimens, a schedule no more frequent than every third day with a defined stop date. This mitigates the futile dose escalation driven by rapid tolerance and limits cumulative 5-HT2B exposure.

• Structured integration in the days afterwards: a scheduled session with a therapist or a written protocol within 48 hours and again at 1 to 2 weeks, since the durable benefit tracks with what follows the experience and prolonged destabilization is most common where nothing follows it. This mitigates post-session destabilization and protects the benefit itself.

Therapeutic Protocol

• The standard full-dose model: the protocol used across modern trials, derived from the North American psychedelic-therapy tradition and formalized by the Basel group under Matthias Liechti and by the Johns Hopkins group, consists of two to three preparatory meetings, a single supervised dosing day of 8 to 12 hours with two attendants present, and two to three integration meetings in the following weeks. Doses are 100 or 200 micrograms of the freebase-equivalent compound. In the trials, either one or two dosing sessions separated by several weeks were used.

• The competing psycholytic model: the European tradition, developed by Hanscarl Leuner and continued in the Swiss limited-medical-use programme under Peter Gasser, uses repeated lower doses of roughly 50 to 100 micrograms embedded in an ongoing course of psychotherapy over months, on the reasoning that material is more workable at a dose that does not dissolve the ordinary self. Neither model has been tested against the other in a head-to-head trial, and the modern evidence base speaks only to the first because that is what was tested — which is a fact about research funding and regulatory pathways, not a demonstration of superiority.

• The low-dose model: typically 5 to 20 micrograms taken every third day or on a weekday-only schedule, popularized in the wider self-experimentation community and studied in home-administered randomized trials by the Auckland group under Suresh Muthukumaraswamy. Controlled data support only a small acute mood effect on dosing days; the sustained benefits reported in surveys have not survived blinded testing. The protocol persists because uncontrolled experience diverges sharply from the trial results.

• Best time of day: morning administration, typically between 8 and 10 a.m., is standard across all trial protocols. The reasoning is that an 8 to 11 hour duration started later runs into the night, and that the residual arousal interferes with sleep. Low-dose protocols follow the same logic for the opposite reason: the objective randomized data showing modestly increased sleep the following night come from morning dosing, whereas afternoon or evening dosing is the most consistent self-reported cause of insomnia.

• Half-life and its practical implication: with a plasma half-life of roughly 3 to 5 hours and nonlinear kinetics, plasma levels have largely cleared by the time subjective effects end, because the slow dissociation from the receptor rather than the plasma concentration determines duration. The practical consequence is that redosing based on how one feels rather than on elapsed time reliably produces an excessive total exposure.

• Single dose versus split dose: every modern trial uses a single oral dose. Splitting is not used and is actively counterproductive at full doses, because a second dose taken 2 to 4 hours in arrives against partially developed tolerance and extends the total duration without proportionally increasing intensity. Low-dose regimens are inherently single-dose by design.

• Genetic polymorphisms influencing protocol choice: CYP2D6 metabolizer status is the most defensible pharmacogenetic input, with poor metabolizers warranting a downward dose adjustment and ultra-rapid metabolizers potentially requiring more. HTR2A variants affecting cortical receptor density plausibly influence the dose needed to reach a given intensity. COMT (catechol-O-methyltransferase, the enzyme that clears dopamine from the prefrontal cortex) and MTHFR (methylenetetrahydrofolate reductase, the enzyme central to folate and methyl-group metabolism) are frequently discussed in this context, but no LSD trial has stratified on either, and there is no defensible dosing rule derived from them.

• Sex-based differences in dosing: women reach higher plasma concentrations at a fixed absolute dose, largely attributable to body composition rather than a distinct pharmacology. Trials have used fixed rather than weight-adjusted dosing without an observed sex difference in outcome or serious adverse events, and no protocol currently adjusts by sex.

• Age-related considerations: modern trials have enrolled up to age 74 with no dose adjustment and no reported loss of efficacy. The considerations that do change with age are reduced hepatic clearance, which lengthens exposure, declining cortical 5-HT2A density, which works in the opposite direction, and accumulated cardiovascular disease, which is the reason a fuller cardiac workup and a lower starting dose are usual practice beyond roughly 65.

• Baseline biomarkers influencing response: current serotonergic antidepressant exposure is by far the strongest predictor of a blunted or absent response and is the biomarker-equivalent that most often determines whether a session works at all. Baseline anxiety severity predicts the magnitude of improvement available. No blood biomarker predicts response.

• Pre-existing conditions influencing response: comorbid depression alongside anxiety is associated with larger absolute improvement across both. High anxiety sensitivity predicts a more difficult acute experience without necessarily predicting a worse outcome, provided support is adequate. Chronic pain populations have been studied only at low doses.

• Setting as an explicit protocol variable: trial protocols specify a quiet, comfortable room, eyeshades, a curated instrumental music programme, and no interruption, and treat these as part of the intervention rather than as ambience. This is one of the few places where the historical literature and the modern literature agree without qualification.

Discontinuation & Cycling

• Not a chronic medication in the full-dose model: the intervention as tested is an episodic one — one to three supervised sessions, with the benefit measured for months afterwards rather than maintained by continued dosing. There is no maintenance regimen, no established re-dosing interval for sustaining benefit, and no evidence on what happens after a fourth or fifth lifetime session. Discontinuation in the ordinary pharmacological sense does not apply.

• No physical dependence or withdrawal syndrome: LSD does not produce physical dependence, and stopping after any pattern of use produces no withdrawal state. It is not self-administered by animals in reinforcement paradigms, and compulsive use is rare. This is consistent across the historical and modern literature and is not seriously contested.

• No tapering protocol is required or established: because there is neither dependence nor withdrawal, low-dose regimens can be stopped abruptly. Where people report a dip in mood on stopping a low-dose schedule, the most parsimonious explanation is loss of an expectancy effect rather than a pharmacological rebound, and no controlled study has demonstrated a withdrawal phenomenon.

• Cycling is mandatory rather than optional for efficacy: rapid tolerance to the subjective effects develops within three to four consecutive daily doses through 5-HT2A downregulation and resolves over roughly 5 to 7 days of abstinence. Every low-dose protocol therefore builds in non-dosing days — the every-third-day schedule and the weekday-only schedule are both tolerance-management devices. Continuous daily dosing does not work and is not practised.

• Defined stop dates for low-dose regimens: because the sustained benefit has not survived blinded testing while the blood-pressure and 5-HT2B exposures accumulate, the practical convention among clinicians who engage with this at all is a bounded trial of 4 to 8 weeks followed by a full stop and an honest assessment, rather than an open-ended schedule. This is a risk-management convention, not an evidence-derived one.

Sourcing and Quality

• No legal consumer supply exists in most jurisdictions: LSD is Schedule I in the United States and equivalently controlled in most countries, meaning there is no regulated retail product, no pharmacopoeial standard applied to anything a consumer can obtain, and no third-party testing infrastructure of the kind that exists for supplements. Any material obtained outside a clinical trial or an authorized programme is of unverified identity, purity, and quantity. This is the defining sourcing fact and it does not have a workaround.

• Adulteration with NBOMe compounds is the specific hazard: the substitution of 25I-NBOMe and related N-methoxybenzyl phenethylamines for LSD on blotter is common and is responsible for essentially all reported deaths attributed to “LSD”. These compounds have a genuine lethal toxicity that LSD does not. Bitterness on the tongue is a practical warning sign, since LSD is tasteless at active doses.

• Reagent testing is the minimum verification available: the Ehrlich reagent turns purple in the presence of indoles including LSD and does not react with NBOMe compounds, and the Hofmann reagent provides a second confirmation. These distinguish compound classes but say nothing about the amount present, which on blotter can vary several-fold between tabs from the same sheet.

• Quantitative drug-checking services provide the only real analysis: in jurisdictions with them — parts of Europe, Canada, Australia, and New Zealand — laboratory services using chromatography and mass spectrometry report both identity and quantity. This is the only route to knowing what a dose actually is, and it is the difference between a 50-microgram and a 200-microgram exposure being a matter of knowledge rather than assumption.

• Legally supplied pharmaceutical-grade material exists but is narrowly restricted: the material used in trials is lysergide D-Tartrate manufactured to pharmaceutical standard, and Switzerland’s limited-medical-use programme supplies it to authorized physicians under individual federal exemption. Enrolment in a registered clinical trial or referral into that programme are the only routes by which a person obtains material of verified identity and dose. No compounding pharmacy in any jurisdiction can legally supply it for general use.

• Analog compounds are not equivalents: 1P-LSD, 1cP-LSD, 1V-LSD and similar prodrugs are sold in some jurisdictions under research-chemical exemptions and convert to LSD in the body, but the conversion efficiency is not precisely characterized, the material is not manufactured to pharmaceutical standard, and the legal status shifts frequently. Their pharmacology is inferred rather than established, and none has been used in a clinical trial.

• Storage and stability considerations: LSD degrades on exposure to light, heat, oxygen, humidity, and chlorine, losing potency measurably over months in poor conditions. Material stored in a cool, dark, dry, sealed container in a freezer retains potency for years, which matters because degradation produces an unknown lower dose rather than an obviously spoiled product.

Practical Considerations

• Time to effect: the acute effect begins 20 to 60 minutes after an oral dose and peaks at 1.5 to 2.5 hours. The therapeutic effect that the trials measure is a different timescale entirely: anxiety reduction is measured at 4 weeks and 16 weeks, not on the day, and the trials show that the benefit is present at the first post-session assessment and is maintained rather than accumulating. For low-dose regimens, no timescale for a sustained effect has been established because no sustained effect has been demonstrated against placebo.

• The dominant common pitfall — dosing without a protected window: underestimating an 8 to 11 hour duration plus a residual day is the most frequent practical error, and it converts a manageable experience into a genuinely harmful one. Next-day cognitive flexibility is measurably impaired even when a person feels recovered.

• Chasing an effect through escalation: because tolerance develops within days, repeating a dose that felt insufficient produces cardiovascular exposure without psychological effect. The correct response to an underwhelming session is a longer interval, not a larger dose.

• Attempting a session while on a serotonergic antidepressant: the most common reason a full dose produces nothing, and a frequent source of the dangerous conclusion that a much larger dose is needed. Receptor downregulation, not dose, is the limiting factor.

• Treating the compound as the whole intervention: the trial protocols include preparation, a controlled setting, a monitor, and structured integration, and the effect sizes in the literature belong to that package. Isolating the molecule from the package is not the same intervention and should not be expected to produce the same outcome.

• Conflating low-dose and full-dose evidence: the anxiety and alcohol findings come from 100 to 200 microgram supervised sessions. The popular low-dose practice has its own, largely null, controlled literature. Evidence for one does not transfer to the other, and this is the most common misreading of the field.

• Regulatory status: LSD is Schedule I in the United States under the Controlled Substances Act, meaning no accepted medical use and no legal possession outside a registered research protocol; it is equivalently controlled under the 1971 United Nations Convention on Psychotropic Substances in most signatory countries. It is not an off-label use of an approved medicine — there is no approved medicine to be off-label from. A standardized preparation holds Breakthrough Therapy designation from the United States Food and Drug Administration for generalized anxiety disorder and is in phase 3 trials, which is a regulatory acceleration pathway and not an approval. Switzerland permits supervised medical use under individual exemption, and several jurisdictions including Australia and parts of the United States have created narrow authorized-prescriber frameworks for related compounds but not for LSD.

• Cost and accessibility: the compound itself is inexpensive to manufacture and the material cost per dose is negligible; the intervention is expensive because it consumes 8 to 12 hours of two trained clinicians’ time plus preparation and integration sessions. Where comparable psychedelic-assisted therapy is delivered commercially, the per-session cost falls in the range of several thousand US dollars, against roughly ten dollars a month for a generic antidepressant. This cost asymmetry is not incidental: insurers and national health systems have a direct and systematic financial incentive to favor the cheap generic comparator, and that incentive plausibly shapes which comparisons get funded, which endpoints guideline committees weight, and how readily a one-off high-cost intervention is judged against a low-cost continuous one. It is a structural source of bias that operates independently of the underlying data, and it runs in the opposite direction to the commercial sponsor’s incentive described under benefits.

• Practical access: for most people the realistic routes are enrolment in a registered clinical trial, referral into the Swiss programme, or nothing. Trial participation carries its own constraints — randomization to placebo, strict exclusion criteria, and geographic limits.

Interaction with Foundational Habits

• Sleep — direct, bidirectional, and timing-dependent. A full dose taken in the morning ends 8 to 11 hours later with residual arousal that commonly delays sleep onset on the dosing night, mediated by continued serotonergic and adrenergic activation; taken later in the day it reliably disrupts the night. In the opposite direction, an objective randomized trial of low doses found approximately 20 to 25 additional minutes of total sleep on the night after a morning dose, without altered sleep architecture, which is consistent with a rebound rather than a sedative effect. Practically, this means morning-only administration and no expectation of normal sleep on a full-dose night, with the following night typically longer than usual.

• Nutrition — indirect, with a fasting convention and a genuine serotonergic overlap. Trial protocols administer the dose after an overnight fast or a light breakfast, primarily to reduce the nausea that affects 40 to 60 percent of participants at full doses and secondarily because food slows absorption and blunts the peak. There is no evidence that any particular diet enhances or reduces efficacy. The real nutritional interaction is serotonergic: direct precursors such as 5-HTP and L-Tryptophan supplements, and St John’s wort, add serotonergic tone and are stopped 2 weeks before a session under trial protocols, whereas ordinary dietary protein does not meaningfully do so. Grapefruit juice inhibits CYP3A4 and can prolong exposure. Appetite is typically suppressed for the duration and returns fully afterwards, so a planned light meal at the end of the session is standard.

• Exercise — indirect and mostly a scheduling constraint. There is no evidence that LSD blunts or enhances training adaptation, and no mechanism that would predict an effect on hypertrophy or endurance adaptation. The interaction is that a full dose raises blood pressure, heart rate, and core temperature for several hours, so exercise on a dosing day adds cardiovascular and thermal load on top of a pressor state and is uniformly excluded from trial protocols. Impaired coordination and judgment make any loaded or technical training unsafe for the full duration and questionable the following morning. Light walking is the practical ceiling on a dosing day. Training resumes normally the day after.

• Stress management — direct and potentiating, in both directions. The compound acutely raises plasma cortisol, prolactin, and oxytocin, so it is a physiological stressor during the session even when the experience is positive. Afterwards, the reported effects run the other way: reduced anxiety scores sustained for months in the trial populations, and increased self-rated well-being in healthy volunteers. Meditation practice and psychedelics interact reciprocally — experienced meditators report deeper acute experiences, and post-session periods are when contemplative practice is most often reported as newly accessible, which is the rationale for scheduling integration work rather than leaving the window unused. The practical corollary is that a session undertaken during a period of acute life stress, poor sleep, or unresolved conflict is substantially more likely to be a difficult one.

Monitoring Protocol & Defining Success

Baseline assessment before any exposure establishes both eligibility and the reference point against which any later change could be interpreted. It is not a formality: the cardiovascular screen determines whether a several-hour pressor load is acceptable, and the baseline echocardiogram is the only way the 5-HT2B valvular question could ever be answered for an individual who intends repeated exposure. A full baseline panel is drawn 1 to 4 weeks before a first session, alongside a structured psychiatric and family history and a review of every medication and supplement.

Ongoing monitoring cadence differs by pattern of use. For the episodic full-dose model, blood pressure and heart rate are measured at baseline, hourly during the session, and at the end of the session, with a follow-up clinical review at 1 week and 4 weeks and a repeat metabolic and hepatic panel at 3 months if more than one session is undertaken. For a repeated low-dose regimen, blood pressure is measured weekly at home, a clinical panel is repeated at 3 months, and an echocardiogram is repeated at 12 months and then every 12 to 24 months for as long as dosing continues.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Blood pressure	110–125 / 65–80 mmHg	Determines tolerance of a several-hour pressor load	Two seated readings on separate days; conventional treatment threshold is 140/90 mmHg, which is well above the functional target. Measure hourly during a session
Resting heart rate	50–70 bpm	Baseline for the 10–20 bpm acute rise; a high resting rate narrows the reserve	Measured on waking; a resting rate above 90 bpm warrants investigation before a full dose
12-lead electrocardiogram (ECG)	Normal sinus rhythm; corrected QT interval under 440 ms in men and 460 ms in women	Detects arrhythmia and conduction abnormality that the acute autonomic load could unmask	ECG is a recording of the heart’s electrical activity. Required over age 50 or with any cardiac symptom. The corrected QT interval is the time for electrical recovery between beats
Transthoracic echocardiogram	No more than trace mitral or aortic regurgitation; no leaflet thickening	The only test that could detect valve change from sustained 5-HT2B receptor activation	Baseline before any regimen intended to exceed 6 months; repeat at 12 months and then every 12–24 months. Not needed for one or two isolated sessions
Alanine aminotransferase (ALT)	10–26 U/L	Confirms hepatic capacity for a compound cleared entirely by the liver	ALT is a liver enzyme released when liver cells are stressed. Conventional laboratories flag only above 40–55 U/L, so a value inside the “normal” range can still be functionally elevated. Fasting not required
Estimated glomerular filtration rate (eGFR)	Above 90 mL/min/1.73 m²	Establishes clearance capacity for metabolites and general physiological reserve	eGFR is a calculated measure of kidney filtering capacity. Reported automatically with a basic metabolic panel; declining values shift the risk balance in older adults
Thyroid-stimulating hormone (TSH)	0.5–2.0 mIU/L	Thyroid dysfunction mimics both anxiety and depression and must be excluded before attributing symptoms or improvement to the intervention	TSH is the pituitary signal that controls thyroid output. Conventional range extends to 4.5 mIU/L; draw in the morning. Pair with free thyroxine (free T4, the main circulating thyroid hormone) if outside range
High-sensitivity C-reactive protein (hs-CRP)	Below 1.0 mg/L	Baseline for the speculative anti-inflammatory hypothesis and a general cardiovascular risk marker	hs-CRP is a sensitive marker of low-grade systemic inflammation. Fasting preferred; invalid within 2 weeks of any infection or injury
Prolactin	4–15 ng/mL in men; 4–23 ng/mL in non-pregnant women	The compound acutely raises prolactin; a baseline distinguishes drug effect from a pre-existing pituitary abnormality	Draw fasting in the morning, at least 1 hour after waking, and avoid after exercise or nipple stimulation
CYP2D6 genotype	Normal (extensive) metabolizer status	Poor metabolizer status predicts a longer, stronger exposure from a standard dose	A one-time pharmacogenomic test, not a monitored value. Reported as poor, intermediate, normal, or ultra-rapid metabolizer

Qualitative markers matter more than laboratory values here, because the intended outcomes are subjective states that no blood test captures. Tracked with a simple weekly written record from 2 weeks before a session to 12 weeks afterwards, they are what actually define success or failure:

• Anxiety and worry burden: frequency and intensity of anticipatory worry, and whether it interrupts activity. This is the endpoint with the strongest trial support and the one most likely to move.
• Mood stability and the presence of anhedonia (a loss of pleasure in things that were previously enjoyable): whether ordinary sources of enjoyment register. Improvement here typically follows the anxiety change rather than preceding it.
• Sleep quality and total sleep time: disrupted on a full-dose night by design; a persistent change beyond the first week is a signal to reassess rather than a normal course.
• Cognitive clarity and working capacity: specifically whether next-day cognitive flexibility has returned, since it is measurably reduced and its persistence beyond 48 hours is atypical.
• Alcohol and other substance intake: measured as drinks per week and heavy-drinking days, which is the outcome the historical randomized trials actually measured.
• Sense of psychological flexibility and openness: willingness to engage with previously avoided material, which is the mechanism the trials propose and the closest available proxy for whether the experience is doing what it is thought to do.
• Persisting visual phenomena: trailing images, halos, or visual snow at any point after a session, which is the early signal for hallucinogen persisting perception disorder and the one qualitative marker where any positive finding is a reason to stop.
• Quality and content of integration: whether the material from the session is being engaged with or avoided, since the durable benefit tracks with what happens afterwards more reliably than with the session itself.

Emerging Research

The near-term picture will be determined by a phase 3 programme that is already fully enrolled or close to it, and by a set of smaller trials extending the compound into indications where the historical literature was suggestive. The findings most likely to matter for a health-optimizing adult are not the psychiatric efficacy results but the long-term cardiac safety data and the continued failure of low-dose regimens to separate from placebo. The phase 3 programme below is sponsored by a commercial developer of the compound, which holds a direct financial interest in the outcome.

• Phase 3 programme in generalized anxiety disorder: two pivotal trials test a single dose of the standardized preparation against placebo, with change in the Hamilton Anxiety Rating Scale at week 12 as the primary endpoint — NCT06809595 (Panorama, 245 participants, active and not recruiting) and NCT06741228 (Voyage, 214 participants, active and not recruiting). These are the trials that will determine whether the compound becomes an approved medicine.

• Phase 3 programme in major depressive disorder: NCT06941844 (Emerge, 149 participants) and NCT07592689 (Ascend, 165 participants) test the same preparation against placebo with change in the Montgomery-Åsberg Depression Rating Scale at week 6 as the primary endpoint. These directly address the conflict between the single-trial depression signal and the calibrated network meta-analysis.

• Modern replication of the alcohol findings: NCT05474989, a phase 2 trial in 128 participants with alcohol use disorder, with percent heavy drinking days as the primary endpoint. It is the first properly controlled test of the 1960s alcoholism result in over fifty years, and the single trial most capable of overturning the best-supported historical claim.

• Cluster headache: NCT05477459, a phase 2 trial in 65 participants with chronic cluster headache measuring weekly attack frequency, and NCT03781128, a phase 2 trial in 30 participants. Together they will convert a long-standing underground practice into either a supported or a refuted indication.

• Existential distress in palliative care: NCT05883540, a phase 2 trial in 60 palliative care patients using state anxiety against an active placebo, which is a stronger comparator design than most of the field uses.

• A shorter-acting analog: NCT07309471 compares the pharmacokinetics of didehydro-LSD against LSD in 24 participants, aiming to establish whether a compound with a shorter duration of action can retain the therapeutic effect. If it succeeds, the 8-to-12-hour session — the single largest barrier to cost and accessibility — becomes negotiable.

• Low-dose administration in premenstrual disorders: NCT07189299, a trial in 150 women measuring change in premenstrual symptom burden, which will be the largest controlled test of a repeated low-dose regimen for a defined clinical endpoint.

• Long-term valvular safety is the most consequential open question: the systematic review by Xu et al., 2026 establishes that the compound engages the 5-HT2B receptor and its downstream fibrotic signalling in valvular tissue, while finding no reported human case of LSD-associated valve disease. No study has yet performed serial echocardiography across a multi-year low-dose regimen, and this is the one gap whose resolution could most change the risk calculus for the longevity-oriented use pattern.

• Whether the subjective experience is necessary at all: the systematic review of psychedelics and neuroplasticity by de Vos et al., 2021 sets out the case that structural plasticity, rather than the acute experience, carries the therapeutic effect. Non-hallucinogenic 5-HT2A agonists built on that premise are entering trials; if they work, the case for LSD specifically weakens considerably, and if they fail, it strengthens.

• Low-dose regimens continue to fail controlled testing: the home-administered randomized trial by Murphy et al., 2023 found acute mood elevation on dosing days without accumulation, and the meta-analysis of microdosing effects on cognition by Pinhas et al., 2026 found no reliable cognitive benefit. Further trials in this direction are more likely to weaken than strengthen the case for the practice.

• Objective physiological endpoints are beginning to replace self-report: the wearable-tracker-based randomized trial by Allen et al., 2024 found increased total sleep time across 3,231 nights the night after a low dose, which is the kind of objective, expectancy-resistant measurement the field has largely lacked. Extending this approach to cardiovascular, inflammatory, and cognitive endpoints is where the low-dose question is most likely to be settled.

• Psychosis risk may be smaller than assumed: the meta-analysis by Sabé et al., 2025 reports incidences of psychedelic-induced psychosis low enough that the authors question whether schizophrenia should remain an absolute exclusion criterion. If replicated in prospective work, this would widen the eligible population; if not, current conservative screening stands.

• Adverse event reporting quality is itself under scrutiny: the meta-analysis by Hinkle et al., 2024 found that only 23.5 percent of studies published since 2005 described a systematic approach to adverse event assessment. The safety profile the field reports is therefore built partly on incomplete ascertainment, and improved pharmacovigilance could move the risk estimates in either direction.

• Longevity biology of psychedelics more broadly: the report by Kato et al., 2025 that psilocin extends replicative lifespan in human cells and improves survival in aged mice has prompted interest in whether serotonergic psychedelics as a class have effects on aging biology. Nothing equivalent has been tested for LSD, and the mouse result awaits independent replication.

Conclusion

LSD is a laboratory-made compound that acts on one family of serotonin receptors and produces a strong, roughly eight-to-twelve-hour change in perception, emotion, and sense of self. The strongest evidence supports a lasting reduction in long-standing anxiety after one or two supervised full-strength sessions, and a reduction in heavy drinking after a single session in older randomized studies. Effects on low mood are less clear, and the popular practice of taking very small, non-intoxicating amounts on a schedule has repeatedly failed to beat dummy treatment in controlled tests. The body has coped well under supervision: brief rises in blood pressure and heart rate, nausea, and headache, with no death attributable to the compound itself. The main documented harms are severe short-term distress during a session, a full day of impaired function, and rare lasting perceptual or psychotic problems in people already vulnerable to them. A theoretical concern about heart valve scarring from years of repeated exposure rests on how the compound binds a second receptor type, with no human cases reported. Much of the newest evidence comes from a company developing the compound as a product, while cheaper established treatments give insurers a standing reason to favor them, and the advocacy and drug-control organizations shaping the debate each depend on their own position prevailing. Illegality, unverified supply, and the need for a supervised day remain the practical limits on what any of this evidence can be applied to.

Top - Benefits - Risks - Protocol